Calcium fructoborate: Plant-based dietary boron as potential medicine for cancer therapy

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 205-215

  Scorei, Ion Romulus ^a  

^a UNIVERSITY OF CRAIOVA   (Romania)

Author keywords

Apoptosis; Boron; Breast Cancer; Calcium Fructoborate; Cervical Cancer; Dietary Supplement; GLUT 5; Lung Cancer; Prostate Cancer; Review

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BORON DERIVATIVE; CALCIUM DERIVATIVE; CALCIUM FRUCTOBORATE; CASPASE 3; DRINKING WATER; FRUITEX B; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 5; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NATURAL PRODUCT; NITRIC OXIDE; UNCLASSIFIED DRUG; BORIC ACID; DRUG DERIVATIVE; FRUCTOSE;

10B NEUTRON CAPTURE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CHEMICAL COMPOSITION; CHEMOPROPHYLAXIS; CRYSTALLIZATION; DIET SUPPLEMENTATION; DIETARY INTAKE; ENZYME ACTIVITY; HUMAN; LUNG CANCER; MACROPHAGE; NEUTRON CAPTURE THERAPY; NONHUMAN; OXIDATIVE STRESS; PROSTATE CANCER; RISK REDUCTION; SOIL PROPERTY; TURKEY (REPUBLIC); UTERINE CERVIX CANCER; CHEMISTRY; DRUG EFFECT; FEMALE; MALE; METHODOLOGY; NEOPLASM; REVIEW;

ANTIOXIDANTS; APOPTOSIS; BORATES; BORON NEUTRON CAPTURE THERAPY; FEMALE; FRUCTOSE; HUMANS; MALE; NEOPLASMS; OXIDATIVE STRESS;

EID: 79955969778     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s145     Document Type: Article

References (110)

1. B Austin: Novel pharmaceutical compounds from marine bacteria. J Appl Bacteriol 67, 461-470 (1989) (Pubitemid 19283762)
2. H Irschik, D Schummer, K Gerth, G Hofle and H Reichenbach: The tartrolons, new boron-containing antibiotics from a myxobacterium, Sorangium cellulosum. J Antibiot 48, 26-30 (1995)
3. K Gademann and C Portmann: Secondary metabolites from Cyanobacteria: Complex structures and powerful bioactivities. Curr Org Chem 12, 326-341 (2008)
4. X Chen, S Schauder, N Potier, A van Dorsselaer, I Pelczer, BL Bassler and FM Hughson: Structural identification of a bacterial quorum-sensing signal containing boron. Nature 415, 545-549 (2002) (Pubitemid 34130611)
5. J Takano, KL Miwa, N Yua, T von Wirén, and T Fujiwara: Endocytosis and degradation of BOR1, a boron transporter of Arabidopsis thaliana, regulated by boron availability. Proc Natl Acad Sci USA 102, 12276-12281 (2005) (Pubitemid 41291165)
6. T Ishii and T Matsunaga: Isolation and characterization of a boronrhamnogalacturonan II complex from cell walls of sugar beet pulp. Carbohydr Res 284, 1-9 (1996) (Pubitemid 26121323)
7. M Kobayashi, T Matoh and J Azuma: Two ch ains of rhamnogalacturonan II are cross-linked by borate-diol ester bonds in higher plant cell walls. Plant Phys 110, 1017-1020 (1996)
8. M Park, Q Li, N Shcheynikov, W Zeng and S Muallem: Na BC1 is a ubiquitous electrogenic Na+-coupled borate transporter essential for cellular boron homeostasis and cell growth and proliferation. Mol Cell 16, 331-341 (2004) (Pubitemid 39504788)
9. M Tanaka and T Fujiwara: Physiological roles and transport mechanisms of boron: perspectives from plants. Pflug Archiv- Eur J Phys 456, 671-677 (2008) (Pubitemid 351692137)
10. NA Petasis: Expanding roles for organoboron compounds versatile and valuable molecules for synthetic, biological and medicinal chemistry. Aust J Chem 60, 795-798 (2007) (Pubitemid 350050541)
11. C Morin: The chemistry of boron analogues of biomolecules. Tetrahedron 50, 12521-12569 (1994) (Pubitemid 24330813)
12. C Baldock, GJD Boer, JB. Rafferty, AR Stuitje and DV Rice: Mechanism of action of diazaborines. Biochem Pharm 55, 1541-1549 (1998) (Pubitemid 28223445)
13. A Jabbour, D Steinberg, VM Dembitsky, A Moussaieff, B Zaks and M Srebnik: Synthesis and evaluation of oxazaborolidines for antibacterial activity against Streptococcus mutans. J Med Chem 47, 2409-2410 (2004) (Pubitemid 38580076)
14. A Jabbour, R Smoum, K Takrouri, E Shalom, B Zaks, D Steinberg, A Rubinstein, I Goldberg, J Katzhendler and M Srebnik: Pharmacologically active boranes. Pure Appl Chem 78, 1425-1453 (2006)
15. SJ Benkovic, SJ Baker, MRK Alley, YH Woo, YK Zhang, T Akama, W Mao, J Baboval, PT Ravi- Rajagopalan, M Wall, LS Kahng, A Tavassoli and L Shapiro: Identification of boronic esters as inhibitors of bacterial cell growth and bacterial methyltransferases, CcrM and MenH. J Med Chem 48, 7468-7476 (2005) (Pubitemid 41743660)
16. SJ Baker, YK Zhang, T Akama, A Lau, H Zhou, V Hernandez, W Mao, MRK Alley, V Sanders and JJ Plattner: Discovery of a new boron - containing antifungal agent, 5-fluoro-1,3- dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 49, 4447-4450 (2006) (Pubitemid 44162669)
17. HB Zhou, KW Nettles, JB Bruning, Y Kim, A Joachimiak, S Sharma, KE Carlson, F Stossi, JA Katzenellenbogen, GL Greene and JA Katzenellenbogen: Elementa l isomerism: a boron- nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands. Chem Biol 14, 659-669 (2007) (Pubitemid 46924836)
18. AH Beddoe: Boron neutron capture therapy. Br J Radiol 70, 665-667 (1997) (Pubitemid 27331121)
19. Y Endo, T Yoshimi and C Miyaura: Boron clusters for medicinal drug design: Selective estrogen receptor modulators bearing carborane. Pure Appl Chem 75, 1197-1205 (2003)
20. L Bolanos, K Lukaszewski, I Bonilla and D Blevins: Why boron? Plant Phys Biochem 42, 907-912 (2004) (Pubitemid 40191574)
21. M Redondo-Nieto, M Reguera, I Bonilla and L Bola: Boron dependent membrane glycoproteins in symbiosome development and nodule organogenesis. A model for a common role of boron in organogenesis. Plant Signal Behav 3, 298-300 (2008) (Pubitemid 351651934)
22. S Collin, R Martin, C Metcalfe, D Gunnell, P Albertsen, D Neal, F Hamdy, P Stephens, J Lane and R Moore: Prostate cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9, 445-452 (2008)
23. Y Cui, MI Winton, ZF Zhang, C Rainey, J Marshall, JB De Kernion and CD Eckhert: Dietary boron intake and prostate cancer risk. Oncol Rep 11, 887-892 (2004)
24. H Adlercreutz: Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ Health Perspect 103(7), 103-112 (1995)
25. WT Barranco, P Hudak and C D Eckhert: Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States) Cancer Cause Control 18, 71-77 (2007) (Pubitemid 46020903)
26. MT Gallardo-Williams, RE Chapin, PE King, GJ Moser, TL Goldworthy, JP Morrison and RR Maronpot: Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxic Pathol 32, 73-78 (2004) (Pubitemid 38249994)
27. WT Barranco, HT Kim, SL Stella Jr., C.D. Eckhert: Boric acid inhibits stored Ca2+ release in DU-145 prostate cancer cells. Cell Biol Toxicol 25, 309-320 (2009)
28. PH Gann, CH Hennekens, J Ma, C Longcope and MJ Stampfer: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88, 1116-1126 (1996)
29. MR Naghi and S Samman: The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects. Biol Trace Elem Res 56, 273-286 (1997) (Pubitemid 27255776)
30. FH Nielsen, CD Hunt, LM Mullen and JR Hunt: Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J 1, 394-397 (1987) (Pubitemid 18033759)
31. MT Gallardo-Williams, RR Maronpot, RN Wine, SH Brunssen and RE Chapin: Inhibition of the enzymatic activity of prostate specific antigen by boric acid and 3- nitrophenyl boronic acid. The Prostate 54, 44-49 (2003) (Pubitemid 36043835)
32. WT Barranco and CD Eckhert: Cellular changes in boric acidtreated DU-145 prostate cancer cells. Br J Cancer 94, 884-890 (2006)
33. C Eckert, W Barranco and D Kim: Boron and prostate cancer a model for understanding boron bio logy. In Advances in Plant and Animal Boron Nutrition Proceedings of the 3rd International Symposium on all Aspects of Plant and Animal Boron Nutrition. Eds: F Xu, HE Goldbach, PH Brown, RW Bell, T Fujiwara, CD Hunt, S Goldberg, L Shi, Springer: NewYork, 291-297 (2007)
34. A Gonzalez, U Peters, JW Lampe and E White: Boron intake and prostate cancer risk. Cancer Cause Control 18, 1131-1140 (2007) (Pubitemid 47498162)
35. DK Espey, XC Wu, J Swan, C Wiggins, AM Jim, E Ward, PA Wingo, HL Howe, LAG Ries, BA Miller, A Jemal, F Ahmed, N Cobb, JS Kaur and BK Edwards: Annual report to the nation on the status of cancer, 1975-2004, featuring cancer inAmerican indians and Alaska natives. Cancer 110, 2119-2152 (2007) (Pubitemid 350100734)
36. SL Meacham, KE Elwell, S Ziegler and SW Carper: Boric acid inhibits cell growth in breast and prost ate cancer cell lines.In: Advances in Plant and Animal Boron Nutrition Proceedings of the 3rd International Symposium on all Aspects of Plant and Animal Boron Nutrition Eds: F Xu, HE Goldbach, PH Brown, RW Bell, T Fujiwara, CD Hunt, S Goldberg, L Shi, Springer: NewYork, 299-306 (2007)
37. FH Nielsen: Biochemical and physiologic consequences of boron deprivation in humans. Environ Health Perspect 102, 7-59 (1994)
38. FH Nielsen: The emergence of boron as nutritionally important throughout the life cycle. Nutrition 16, 512-514 (2000) (Pubitemid 30445092)
39. CD Hunt: Regulation of enzymatic activity: one possible role of dietary boron in higher animals and humans. Biol Trace Elem Res 66, 205-225 (1998) (Pubitemid 29093984)
40. R Scorei, VM Cimpoiasu and D Iordachescu: In vitro evaluation of the antioxidant activity of calcium fructoborate. Biol Trace Elem Res 107, 127-134 (2005)
41. R Scorei, R Ciubar, C Iancu, V Mitran, A Cimpean and D Iordachescu: In vitro effects of calcium fructoborate on fMLPstimulated human neutrophil granulocytes. Biol Trace Elem Res 118, 27-37 (2007) (Pubitemid 47509506)
42. D Miljkovic, IR Scorei, VM Cimpoiasu and ID Scorei: Calcium fructoborate: plant-based dietary boron for human nutrition. J Diet Suppl 6, 211-226 (2009)
43. MB Schabath, X Wu, R Vassilopoulou-Sellin, AA Vaporciyan and M R Spitz: Hormone repla cement therapy and lung cancer risk. A case-control analysis clinical. Cancer Res 10, 113-123 (2004) (Pubitemid 38114169)
44. Y Wang, Y Zhao and X Chen: Experimental study on the estrogen like effect of boric acid. Biol Trace Elem Res 121, 160-170 (2008) (Pubitemid 351378042)
45. S Mahabir, MR Spitz, SL Barrera, YQ Dong, C Eastham and MR Forman: Dietary boron and hormone replacement therapy as risk factors for lung cancer in American women. J Epidemol 167, 1070-1080 (2008) (Pubitemid 351601244)
46. DG Hoel, DL Davis, AB Miller, EJ Sondik, AJ Swerdlow: Trends in cancer mortality in 15 industrialized countries, 1969-1986. J Natl Ca ncer Inst 84(5), 313-320 (1992)
47. G Ursin, MC Pike, S Preston-Martin, G d'Ablaing and RK Peters: Sexual, reproductive and other risk factors for adenocarcinoma of the cervix: results from a populat ion-based case control study (California, United States) Cancer Cause. Control 7, 391-401 (1996)
48. N Ylitalo, P Sorensen, A Josefsson, M Frisch, P Sparen, J Ponten, U Gyllensten, M Melbye and HO. Adami: Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer 81, 357-365 (1999) (Pubitemid 29165193)
49. X Castellsague, XF Bosch and N Munoz: Environmental c ofactors in HPV carcinogenesis. Virus Res 89, 191-199 (2002)
50. BS Sayli, E Tuccar and AH Ellan: An assessment of fertility and infertility in boron-exposed Turkish subpopulations, Part 3: Evaluation of fertility among sibs and in borate families. Biol Trace Elem Res 81, 255-267 (2001) (Pubitemid 32848481)
51. A Simsek, SY Velioglu, LA Coskun and BS Sayl: Boron concentrations in selected foods from borateproducing regions in Turkey. J Sci Food Agric 83, 586-592 (2003) (Pubitemid 36557608)
52. M Korkmaz, E Uzgo, S Bakirdere, F Aydin and Y Ataman: Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells. Environ Toxicol 22, 17-25 (2007)
53. H Stoppler, D Koval and R Schlegel: The serine prote ase inhibitors TLCK and TPCK inhibit the in vitro immortalization of primary human keratinocytes by HPV- 18 DNA. Oncogene 13, 1545-1548 (1996) (Pubitemid 26354203)
54. BR Whitley, D Palmieri, CD Twerdi and FC Church: Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 296, 151-162 (2004) (Pubitemid 38624637)
55. C Wagner, CF Curotto, RP Diez and EJ Bara: Experimental and theoretical studies of calcium fructoborate. Biol Trace Elem Res 122, 64-72 (2008)
56. P Rotaru, R Scorei, A Harabor and MD Dumitru: Thermal analysis of a calc ium fructoborate sample. Thermochimica Acta 506, 8-13 (2010)
57. M Benderdour, T Van Bui, K Hess, A Dicko, F Belleville, and B Dousset: Effects of boron derivatives on extracellular matrix formation. J Trace Element Med Biol 14, 168-173 (2000)
58. CP Turner, A M Toye, and OTG Jones: Keratinocyte superoxide generation. Free Radical Biol Med 24, 401-407 (1998) (Pubitemid 28008784)
59. DC Hunt and PJ Idso: Dietary boron as a physiological regulator of the normal inflammatory response: a review and current research progress. J Trace Elements Exp Med 12, 221-233 (1999)
60. DC Hunt: Dietary boron: an overview of the evidence for its role in immune function. J Trace Elements Exp Med 16, 291-306 (2003)
61. R Kettritz, RJ Falk, JC Jennette and ML Gaido: Neutrophil superoxide release is required for spontaneous and FMLPmediated but not for TNF alpha-mediated apoptosis. J Am Soc Nephrol 8, 1091-1100 (1997)
62. D Granfeldt, M Samuelsson and A Karlsson: Capacitative Ca2+ influx and activation of the neutrophil respiratory burst. Different regulation of plasma membrane-and granulelocalized NADPH-oxidase. J Leukoc Biol 71, 611-617 (2002)
63. CD Hunt: Regulation of enzymatic activity: one possible role of dietary boron in higher animals and humans. Biol Trace Elem Res 66, 205-225 (1998) (Pubitemid 29093984)
64. K Uchimura, A Nagasaka, R Hayashi, M Makino, M Nagata, H Kakizawa, T Kobayashi, K Fujiwara, T Kato, K Iwase, R Shinohara, K Kato and M Itoh: Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patien ts with diabetes mellitus. J Diabet Comp 13, 264-270 (1999) (Pubitemid 30182606)
65. RI Scorei, C Ciofrangeanu, R Ion, A Cimpean, B Galateanu, V Mitran and D Iordachescu: In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. Biol Trace Elem Res 135, 334- 344 (2010)
66. A Zychlinsky, C Fitting, JM Cavaillon and PJ Sansonetti: Interleukin 1 is released by murine macrophages during apoptosis induced by Shigella flexneri. J Clin Invest 94, 1328-1332 (1994) (Pubitemid 24286479)
67. J Cao, L Jiang, X Zhang, X Yao, C Geng, X Xue and L Zhong : Boric acid inhibits LPS-induced TNF-alpha formation through a thiol-dependent mechanism in THP-1 cells. J Trace Elem Med Biol 22, 189-195 (2008)
68. TA Armstrong and JW Spears: Effect of boron supplementation of pig diets on the production of tumor necrosis factor-alpha and interferon-gamma. J Anim Sci 81, 2552-2561 (2003) (Pubitemid 38571659)
69. M Benderdour, K Hess, M Dzondo-Gadet, B Dousset, P Nabet and F Belleville: Effect of boric acid solution on cartilage metabolism. Biochem Biophys Res Commun 234, 263-268 (1997) (Pubitemid 27267571)
70. M Benderdour, K Hess, M Dzondo-Gadet, P Nabet, F Belleville and B Dousset: Boron modulates extracellular matrix and TNFα sythesis in human fibroblasts. Biochem Biophys Res Commun 246, 746-751 (1998) (Pubitemid 28420929)
71. J Yao, N Mackman, TS Edgington and ST Fan: Lipopolysaccharide induction of the tumor necrosis factoralpha promoter in human monocytic cells. Regulation by egr- 1, c-jun and NF-kappaB transcription factors. J Biol Chem 272, 17795-17801 (1997) (Pubitemid 27311220)
72. TK Means, RP Pavlovich, D Roca, MW Vermeulen and MJ Fenton: (2000) Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations. J Leukocyte Biol 67, 885-893 (2000)
73. EY Tsai, JV Falvo, AV Tsytsykova, AK Barczak, AM Reimold, LH Glimcher, MJ Fenton, DC Gordon, IF Dunn and AE Goldfeld: A lipopolysaccharide-sp ecific enhancer complex involving Ets, Elk-1, Sp1 and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo. Mol Cell Biol 20, 6084-6094 (2000) (Pubitemid 30613056)
74. S Pradervand, MR Maurya and S Subramaniam: Identification of signaling components required for the prediction of cytokine release in RAW 264.7 macrophages. Genome Biol 7, R11 (2006)
75. PC Calder: N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38, 343-352 (2003) (Pubitemid 36724290)
76. D. Rees, E.A. Miles, T. Banerjee, S.J. Wells, C.E. Roynette, K.W. Wahle and P.C. Calder: Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. Am J Clin Nutr 83, 331-342 (2006) (Pubitemid 44713195)
77. I Hardardóttir and JE Kinsella: Increasing the dietary (n-3) to (n-6) polyunsaturated fatty acid ratio increases tumor necrosis factor production by murine resident peritoneal macrophages without an effect on elicited peritoneal macrophages. J Nutr 122, 1942-1951 (1992)
78. L Ferrucci, A Cherubini, S Bandinelli, B Bartali, A Corsi, F Lauretani, A Martin, C Andres-Lacueva, U Senin and JM Guralnik: Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439-446 (2006) (Pubitemid 43236907)
79. FH Nielsen and BJ Stoecker: Boron and fish oil have different beneficial effects on strength and trabecular microarchitecture of bone, J Trace Elem Med Biol 23(3), 195-203 (2009)
80. C Nathan and QW Xie: Nitric oxide synthases. Roles, tolls, and controls. Cell 78, 915-918 (1994) (Pubitemid 24292319)
81. JE Albina, S Cui, RB Mateo and JS Reichner: Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150, 5080-5085 (1993) (Pubitemid 23150375)
82. Y.J. Jeon, K.K. Young, M. Lee, S.M. Park, S.B. Han and H.M. Kim: Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and Nuclear Factor-kB/Rel in lipopolysaccharidestimulated macrophages. J Pharmacol Exp Ther 294, 548-554 (2000) (Pubitemid 30490828)
83. R Beyaert, A Cuenda, W Vanden Berghe, S Plaisance, JC Lee, G Haegeman, P Cohen and W Fiers: The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 15, 1914-1923 (1996) (Pubitemid 26119694)
84. AD Foey, SL Parry, LM Williams, M Feldmann, BM Foxwell and FM Brennan: Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-α: Role of the p38 and p42/44 mitogen activated protein kinases. J Immunol 160, 920-928 (1998) (Pubitemid 28049336)
85. A Eigler, J Moeller and S Endres S: Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J Immunol 154, 4048-4054 (1995)
86. JA Williams and E Shacter: Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase -1 and -2. J Biol Chem 272, 25693-25699 (1997) (Pubitemid 27438886)
87. R van den Berg, JA Peters and H van Bekkum: The structure and (local) stability constants of borate esters of mono- and di-saccharides as studied by 11B and 13C NMR spectroscopy. Carbohydr Res 253, 1-12 (1994) (Pubitemid 24096056)
88. Q Luan, T Desta, L Chehab, VJ Sanders, J Plattner and DT Graves: Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res 87, 148 (2008)
89. LH Mattingly, AR Gault and WJ Murphy: Use of systemic proteasome inhibition as an immunemodulating agent in disease. Endocr Metab Immune Disord Drug Targets 7, 29-3 (2007)
90. R Scorei, R Ciubar, CM Ciofrangeanu, V Mitran, A Cimpean and D Iordachescu: Comparative effects of boric acid and calcium fructoborate on breast cancer cells. Biol. Trace Elem. Res 122, 197-205 (2008)
91. R Scorei and R Popa: Boron-containing Compounds as Preventive and Chemotherapeutic Agents for Cancer. Anti Canc Agents Med Chem 10(4), 346-351 (2010)
92. WT Barranco and CD Eckhert: Boric acid inhibits humane prostate cancer cell proliferation. Cancer Lett 216, 21-29 (2004) (Pubitemid 39410492)
93. WT Barranco and CD Eckhert: Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 94, 884-890 (2006)
94. F Chen, D Chang, M Goh, SA Klibanov and M Ljungman: Role of p53 i n cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 11, 239-246 (2000) (Pubitemid 30347203)
95. TR. Shirangi, A Zaika and UM Moll: Nuclear degradation of p53 occurs durin g down-regulation of the p53 response after DNA damage. FASEB J 16 (3), 420-422 (2002)
96. GL Locher: Biological effects and therapeutic possibilities of neutrons, Am J Roentgenol Radium Ther Nucl Med 36, 1-13 (1936)
97. F Rolf, JA Barth, M Coderre, HV Graça and TE Blue : Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects. Clin Cancer Res 11 (11), 3987-4002 (2005) (Pubitemid 40791562)
98. GI Bell, T Kayano, JB Buse, CF Burant, J Takeda, D Lin, H Fukumoto and S Seino: Molecular biology of mammalian glucose transporters. Diabetes Care 13, 198-208 (1990) (Pubitemid 20092107)
99. G Boudry, CI. Cheeseman and MH Perdue. Psychological stress impairs Na-dependent glucose absorption and increases GLUT2 expression in the rat Comp Physiol 292, R862-R867 ( 2007)
100. V Douard and RP Ferraris: Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab 295, E227-E237 ( 2008)
101. J Payne, F Maher, I Simpson, L Mattice, P Davies: Glucose transporter glut 5 expression in microglial cells. Glia 21(3), 327-331 (1997) (Pubitemid 27491052)
102. F Nualart, A Godoy and K Reinicke: Expression of the hexose tra nsporters GLUT1 and GLUT2 during the early development of the human brain. Brain Res 824, 97-104 (1999) (Pubitemid 29222890)
103. VA Funari, VL Herrera, D Freeman and DR Tolan: Genes required for fructose metabolism are expressed in Purkinje cells in the cerebellum. Brain Res Mol Brain Res 142: 115-122, (2005) (Pubitemid 41683129)
104. GJ Mantych, DE James and SU Devaskar: Jejunal/kidney glucose transporter isoform (Glut-5) is expresse d in the human blood-brain barrier. Endocrinology 132, 35-40 ( 1993) (Pubitemid 23019479)
105. HJ Shu, K Isenberg, RJ Cormier, A Benz and CF Zorumski: Expression of fructose sensitive glucose transporter in the brains of fructose-fed rats. Neuroscience 140, 889-895 (2006) (Pubitemid 43767457)
106. CF Burant, J Takeda, E Brot-Laroche, GI Bell and NO Davidson: Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 267(21), 14523-14526 (1992)
107. J Chesney: 6-Phosphofructo-2-kinase/fructose-2, 6- bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care 9, 535-539 (2006) (Pubitemid 44258026)
108. SP Zamora-Leon, DW Golde, II Concha, CI Rivas, F Delgado-Lopez, J Baselga, F Nualart and JC Vera: Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci USA 93, 1847-1852 (1996) (Pubitemid 26079842)
109. KK Chan, JY Chan, KK Chung and KP Fung: Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J Cell Biochem 93, 1134-1142 (2004) (Pubitemid 44264127)
110. A Godoy, V Ulloa, F Rodriguez, K Reinicke, AJ Yanez, L Garcia Mde, RA Medina, M Carrasco, S Barberis, T Castro, F Martinez, X Koch, JC Vera, MT Poblete, CD Figueroa, B Peruzzo, F Perez and F Nualart: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207, 614-627 (2006) (Pubitemid 43668223)